



54647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 016777-0309

Applicants: Kaare M. GAUTVIK et al.

Title: PRODUCTION OF HUMAN PARATHYROID HORMONE
FROM MICROORGANISMS

Appl. No.: 09/287,332

Filing Date: 04/07/1999

Examiner: R. Landsman

Art Unit: 1647

AMENDMENT TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a previous assertion of Small Entity status.

☐ Assertion of Small Entity status is enclosed.

☒ The fee required is calculated below:

	Claims As Amended		Previously Paid For		Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	6	-	36	=	0	x	\$18.00	=	\$0.00
Independent Claims:	1	-	13	=	0	x	\$88.00	=	\$0.00
First presentation of any Multiple Dependent Claims:						+	\$300.00	=	\$0.00
CLAIMS FEE TOTAL								=	\$0.00

- ☐ Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/> Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/> Extension for response filed within the second month:	\$430.00	\$0.00
<input type="checkbox"/> Extension for response filed within the third month:	\$980.00	\$0.00
<input type="checkbox"/> Extension for response filed within the fourth month:	\$1,530.00	\$0.00
<input type="checkbox"/> Extension for response filed within the fifth month:	\$2,080.00	\$0.00
EXTENSION FEE TOTAL:		\$0.00
<input type="checkbox"/> Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$110.00	\$0.00
<input checked="" type="checkbox"/> Information Disclosure Statement Fee under 37 C.F.R. 1.17(p):	\$180.00	\$180.00
CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:		\$0.00
<input type="checkbox"/> Small Entity Fees Apply (subtract ½ of above):		\$0.00
TOTAL FEE:		\$180.00

- ☒ A check in the amount of **\$180.00** is enclosed.


- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

October 28, 2004
Date

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5538
Facsimile: (202) 672-5399


Michele M. Simkin
Attorney for Applicants
Registration No. 34,717



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 016777-0309

Applicants: Kaare M. GAUTVIK et al.
Title: PRODUCTION OF HUMAN PARATHYROID HORMONE
FROM MICROORGANISMS
Appl. No.: 09/287,332
Filing Date: 04/07/1999
Examiner: R. Landsman
Art Unit: 1647

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56, and to comply with the Examiner's Request for Information in an office action dated February 27, 2004, in connection with the above-referenced application. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

10/29/2004 CCHAU1 00000111 09287332

01 FC:1806

180.00 DP

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

October 28, 2004


Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5538

Facsimile: (202) 672-5399


for Michele M. Simkin
Attorney for Applicants
Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Filed: October 28, 2004 (use as many sheets as necessary)		Complete if Known Application Number: 09/287,332 Filing Date: 04/07/1999 First Named Inventor: Kaare M. GAUTVIK et al. Group Art Unit: 1647 Examiner Name: R. Landsman Attorney Docket Number: 016777-0309	
Sheet	1	of	2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,208,041		SINDREY	05/04/1993	
	A2	5,420,242		GAUTVIK et al.	05/30/1995	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A3	WO	84/01173	A1	IMMUNO NUCLEAR CORP.	03/29/1984		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	SINGH ET AL., "Synthesis, Secretion and Processing of α -Factor-Interferon Fusion Proteins in Yeast," <i>Nucleic Acids Research</i> , Vol. 12, No. 23, 1984, pp. 8927-8938.	
	A5	MATHAVAN ET AL., "High-Level Production of Human Parathyroid Hormone in <i>Bombyx Mori</i> Larvae and BmN Cells Using Recombinant Baculovirus," <i>Gene</i> , Vol. 167, 1995, pp. 33-39.	
	A6	HØGSET ET AL., "Expression and Characterization of a Recombinant Human Parathyroid Hormone Secreted by <i>Escherichia coli</i> Employing the Staphylococcal Protein A Promoter and Signal Sequence," <i>The Journal of Biological Chemistry</i> , Vol. 265, No. 13, May 5, 1990, pp. 7338-7344.	
	A7	OLSTAD ET AL., "Differences in Binding Affinities of Human PTH(1-84) Do Not Alter Biological Potency: A Comparison Between Chemically Synthesized Hormone, Natural and Mutant Forms," <i>Peptides</i> , Vol. 15, No. 7, 1994, pp. 1261-1265.	
	A8	REPPE ET AL., "Characterization of a K26Q Site-Directed Mutant of Human Parathyroid Hormone Expressed in Yeast," <i>The Journal of Biological Chemistry</i> , (August 5, 1991), Vol. 266, No. 22, pp. 14198-14201.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.